BBLG

Bone Biologics Corp is a development-stage biotechnology company focused on bone regeneration therapeutics using the latest advances in orthopedic medicine. Based in Los Angeles, California, the company is developing a portfolio of bone graft products designed to improve bone healing in spinal fusion and other orthopedic procedures. Bone Biologics' lead product candidate is NELL-1/DBX, a recombinant protein therapeutic intended to promote bone formation and enhance the success rates of spinal fusion surgeries. The company's technology is based on pioneering research from UCLA involving the NELL-1 protein, which has demonstrated superior bone regeneration properties in preclinical and clinical studies. NELL-1 works through a different biological pathway than existing bone morphogenetic proteins (BMPs), potentially offering advantages in safety and efficacy. The therapeutic candidate is being developed in combination with demineralized bone matrix (DBX) to create an off-the-shelf bone graft substitute that could reduce the need for autograft bone harvesting. Bone Biologics operates in the orthopedic biologics market, which includes products used to facilitate bone healing in trauma, spinal fusion, joint reconstruction, and dental procedures. The company is advancing its programs through clinical development with the goal of obtaining regulatory approval and commercializing innovative bone regeneration solutions. The development program faces the typical risks and challenges associated with biotechnology development including clinical trial outcomes, regulatory pathways, and eventual market acceptance.